将NSAID转移到线粒体中,以诱导癌细胞的亡
Tripti Mishra1, Antara Goswami1, Aman Bajpai1
1Department of Chemistry, Indian Institute of Technology (IIT) Gandhinagar, Palaj, Gandhinagar, Gujarat, 382355, India.
Chemistry, an Asian journal
|August 30, 2024
概括
研究人员开发了一种新型的麦克洛芬胺酸衍生物,该衍生物向癌细胞线粒体. 这种化合物通过触发细胞亡来有效诱导癌细胞死亡,为癌症治疗提供了一种新的方法.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 线粒体功能障碍是替代癌症治疗的有希望的策略.
- 非类固醇抗炎药物 (NSAIDs) 显示出破坏癌细胞线粒体的潜力.
- 针对特定于线粒体的NSAIDs是一个重大挑战.
研究的目的:
- 合成和评估新型NSAID衍生品,用于针对性线粒体药物输送.
- 研究这些衍生物在诱导癌细胞死亡方面的潜力.
主要方法:
- 麦克洛芬胺酸和纳普罗衍生物与三酸的合成.
- 在宫癌 (HeLa),乳腺癌 (MCF7) 和结肠癌 (HCT-116) 细胞系中检查合成的化合物.
- 评估线粒体损伤,活性氧物种 (ROS) 生成,亡标志物和细胞死亡.
主要成果:
- 甲基胺酸衍生物 (8A3) 与链接到三4-甲基) 酸有效向线粒体.
- 化合物8A3在HCT-116细胞中诱导了线粒体外膜通透 (MOMP) 和ROS生成.
- 8A3通过抑制Cox-2,减少Bcl-2/Bcl-xl,并分裂Caspase-3/9,从而触发了细胞亡,导致显著的HCT-116细胞死亡.
结论:
- 成功合成了一种针对线粒体的新型麦克洛芬胺酸衍生物 (8A3).
- 这种衍生物显示出作为癌症治疗研究的化学生物学工具的潜力.
- 这些发现强调了基于NSAID的线粒体向在癌症治疗中的治疗潜力.
相关概念视频
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Electron Transport Chain: Complex I and II
12.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The Extrinsic Apoptotic Pathway
6.3K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.3K
Apoptosis
11.3K
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
11.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120


